Previous studies showed that the increase in CLL viability induced by sustained BCR engagement (using anti-IgM antibodies or B-cell activating factor/BAFF) is accompanied by STAT3 activation and Mcl-1 upregulation [75,76,77]. This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.